WALTHAM, Mass., Nov. 5, 2019 /PRNewswire/ -- Sojournix, a clinical stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women's health and neuroendocrine disorders, announces that Daniel Grau, Chief Executive Officer of Sojournix, will present at the Stifel 2019 H

SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended September 30, 2019, and provided an update on its clinic

SAN JOSE, Calif., Nov. 5, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cance

ALPHARETTA, Ga., Nov. 5, 2019 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2019 results and revised its full-year 2019 outlook.

MINNEAPOLIS, Nov. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 9:45 a.m. CST. The conference will be held a

ST. LOUIS, Nov. 5, 2019 /PRNewswire/ -- Home State Health recently provided the funding to purchase  two Spot Vision Screeners for Kids Vision For Life - St. Louis (KVFL). These screeners help to accurately test individuals for eye disorders and other vision problems. Additionally, they allow KVFL to screen children who are non-

TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as monotherapy and combination therapy in first-line patients with advanced non-small cell lung cancer (NSCLC). Regeneron is currently rec

MINNEAPOLIS, Nov. 5, 2019 /PRNewswire/ -- DaVita Clinical Research (DCR) is set to present 10 research abstracts from company representatives and medical professionals at the American Society of Nephrology (ASN) annual

SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in the following industry and investor conferences in November:

TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ --Third quarter 2019 revenues increased 23% to $2.05 billion versus third quarter 2018 Third quarter EYLEA® U.S. net sales increased 16% to $1.19 billion versus third quarter 2018 Du